Evaluate the Efficacy and Safety of the Combined Use of a Sodium-glucose Cotransporter 2 (iSGLT2) Inhibitor and a Dipeptidyl Peptidase-4 (iDPP -4) Inhibitor in the Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin

The present study aims to evaluate the efficacy and safety of different combinations of oral antidiabetics in patients with inadequate glycemic control on metformin monotherapy.

Start Date30 Nov 2026

Sponsor / Collaborator

Eurofarma Laboratórios SA

NCT06851962

/ Not yet recruitingPhase 4IIT

Single-blinded, Double-arm, Controlled, Randomized, Multicentre Clinical Trial to Evaluate the Impact of Pharmacogenetic-guided Treatment in Patients With Insufficiently Controlled Type 2 Diabetes

The goal of this clinical trial is to assess the efficacy of a pharmacogenetics-guided treatment, compared to standard optimized treatment, in patients with inadequately controlled type 2 diabetes. The main questions it aims to answer are:
* Is the disease better controlled when the treatment prescribed is based on the participant's pharmacogenetic profile?
* What medical problems do participants experience while taking the treatment?
Participants will:
* Take the treatment described according to the Summary of Product Characteristics (SmPC).
* Visit the clinic once every 12 weeks for checkups and tests.
* Keep a diary of their symptoms to inform the Investigator.

Start Date01 Apr 2025

Sponsor / Collaborator-

CTRI/2024/10/075543

/ Not yet recruitingNot Applicable

An open label, balanced, randomized, two-treatment, two period, two-sequence, single dose, crossover, oralbioequivalence study of Sitagliptin 50 mg & MetforminHydrochloride 500 mg (extended release) Tablets by SunGlowLifescience Private Ltd., with Janumet XR 50 mg/ 500 mgtablets {Sitagliptin and metformin HCl (extended release) tablets 50 mg/500 mg} of Merck Sharp & Dohme Corp inhealthy, adult, human subjects under fed conditions. - NIL

Start Date04 Nov 2024

Sponsor / Collaborator

SunGlow Lifescience Pvt Ltd.

100 Clinical Results associated with Sitagliptin Phosphate

100 Translational Medicine associated with Sitagliptin Phosphate

100 Patents (Medical) associated with Sitagliptin Phosphate

3,669

Literatures (Medical) associated with Sitagliptin Phosphate

01 Jun 2025·JOURNAL OF MOLECULAR STRUCTURE

Exploring docking studies for the designing of pyrrolidine and thiazole conjugate as an anti-diabetic agent

Author: Bhat, Aeyaz Ahmad ; Singh, Iqubal ; Garg, Sourbh Suren

This study highlights the crucial role of nitrogen and sulfur-containing five-membered heterocyclic scaffolds in the development of antidiabetic drugs, focusing on the versatile pyrrolidine and thiazole derivativesSelected compounds (1a-1k) were evaluated for their ability to inhibit key enzymes related to diabetes such as dipeptidyl peptidase-IV (DPP-IV), α-glucosidase and α-amylase.Notably, derivatives 1d and 1 g emerged as most active among all tested derivatives as α-amylase inhibitors with IC₅₀ values of 10.17 and 13.67 μg/mL.Derivative 1d also showed significant activity with IC₅₀ values of 23.07 μg/mL and 15.40 μg/mL against DPP-IV and α-glucosidase, resp.The SAR study suggested that incorporation of sulfur and nitrogen heteroatoms, along with amide and carboxylic groups, significantly enhanced their inhibitory potency.These findings underscore the importance of structural optimization in drug design.Pyrrolidine, thiazole, fluorine and carbohydrate moieties were used for the designing of a new hybrid (3).The docking study of the hybrid (3) discovered the highest binding score for DPP-IV as -8.8, α-glucosidase as -10.2 and α-amylase as -8.5 kcal/mol.The physicochem. and ADMET characteristics of hybrid 3 suggest it possesses drug-like properties and adequate pharmacokinetic and safety profiles.Based on the results, it can be expected that hybrid (3) can be an effective anti-diabetic agent.

01 May 2025·JOURNAL OF HAZARDOUS MATERIALS

Predicting sorption of diverse organic compounds in soil-water systems: Meta-analysis, machine learning modeling, and global soil mapping

Article

Author: Zhang, Kai ; Sun, Jiachun ; Zhang, Huichun

In recent decades, the environmental detection of various organic compounds (OCs) has highlighted the limitations of conventional soil-water sorption models, which simplify complex experimental conditions and often overlook OCs with polyfunctional and ionizable structures. To address these shortcomings, we compiled a comprehensive soil-water sorption dataset encompassing 20,945 data points for 419 OCs with various functional groups and 1037 different soils. Meta-analysis of the dataset revealed the trends of soil sorption associated with OC substructures, soil properties, and solution conditions. Machine learning models employing the XGBoost algorithm, in conjunction with MACCS fingerprints and experimental conditions, were developed to cover the entire spectrum of speciation for cationic, neutral, and anionic species. Among these, the individual models tailored to each speciation achieved an overall root-mean-square-error value of 0.32 for log K_d. Model interpretation revealed that the models correctly understood the contributions of various substructures, such as multiple aromatic rings and nitrogen or oxygen atoms, to sorption. The models were also found to accurately capture isotherm nonlinearity and the pH effect on the sorption of ionizable OCs. Finally, utilizing soil properties from the Harmonized World Soil Database, the models predicted the sorption of diverse OCs based on global soil properties under simulated environmental scenarios.

01 Apr 2025·SEPARATION AND PURIFICATION TECHNOLOGY

Using artificial neural networks to elucidate retention interactions on stationary phases with amine moieties dedicated to supercritical fluid chromatography

Author: Plachka, Katerina ; Gazarkova, Tatana ; Pilarova, Veronika ; Plachká, Kateřina ; Nováková, Lucie ; Pilařová, Veronika ; Svec, Frantisek ; Švec, František ; Garrigues, Jean-Christophe ; Novakova, Lucie ; Gazárková, Taťána

The retention mechanisms of small mols. on a wide range of stationary phases using different mobile phase compositions are one of the most discussed topics in current state-of-the-art supercritical fluid chromatog. (SFC).Although various theories have been published on retention behavior, prediction, and stability over time, an in-depth insight into the mechanisms is still lacking.Our study focused on the description of the retention mechanisms on columns with amine moieties, i.e., 2-ethylpyridine, 2-picolylamine, 1-aminoanthracene, and diethylamine, dedicated to SFC, using three different compositions of organic modifier, i.e., methanol, methanol + 10 mmol/L NH₃, and methanol + 2% H₂O, in CO₂.An extensive set of analytes characterized by more than 200 mol. descriptors was used.The importance of the effect of each mol. descriptor on the retention behavior was determined by artificial neural networks.Thus, the descriptors increasing and/or decreasing retention on individual columns using different mobile phase compositions were defined.The data collected over one year of column use were statistically evaluated to describe the retention behavior of small mols. on the tested stationary phases using three organic modifiers and to describe the changes in retention behavior over time.As the development of the SFC method can be laborious and time-consuming, this publication offers a detailed description of the interactions taking place between the analyte and the SFC stationary phase.Understanding these fundamental processes will enable faster development of SFC methods using quality-by-design principles.

104

News (Medical) associated with Sitagliptin Phosphate

30 Mar 2025

·pipelinereview.com

Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

BAGSVAERD, Denmark I March 29, 2025 I Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide) significantly reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD) 1 . These new data from the phase 3b trial were featured during a late-breaking clinical trial session at the American College of Cardiology’s (ACC) Annual Scientific Session and Expo in Chicago, US and simultaneously published today in New England Journal of Medicine 2 . The SOUL trial achieved its primary endpoint, demonstrating a 14% reduction in risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes and CVD and/or CKD when treated with Rybelsus ® compared to placebo. Each component of MACE, being CV death, nonfatal myocardial infarction and nonfatal stroke, contributed to the risk reduction 1 . “Heart attacks and strokes are the leading causes of disability and death for people with type 2 diabetes, and there is a need for new, patient-centric treatments to help manage this risk,” said Darren McGuire, MD, Distinguished Chair in Cardiovascular Science and Teaching Professor of Medicine at UT Southwestern, US, and SOUL steering committee co-chair. “The SOUL trial in adults with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) and/or CKD demonstrated significant reductions in the risk of major cardiovascular events including heart attack, stroke and CV death in those treated with oral semaglutide vs placebo. The proven cardiovascular benefit reflects a profound clinical impact for our patients who now have an oral option to improve health outcomes.” Cardiometabolic diseases span a wide range of conditions, including cardiovascular and peripheral artery disease, type 2 diabetes and chronic kidney disease 3 . When combined, these conditions represent the leading cause of death globally 4 . Having type 2 diabetes directly increases the risk of developing interconnected cardiometabolic diseases, while also contributing to the progression of other cardiovascular risk factors 5 . Nearly one in three adults with type 2 diabetes have CVD 6 . “Novo Nordisk continues to evolve its focus beyond diabetes and obesity towards a broader spectrum of metabolic and cardiovascular health,” said Martin Holst Lange, executive vice president for Development at Novo Nordisk. “These data, alongside our other data being presented at ACC, reinforce the comprehensive set of health benefits of semaglutide, making it a strong option for healthcare professionals addressing the spectrum of metabolic and cardiovascular health – and our continued leadership in the space.” The overall safety profile of oral semaglutide in SOUL was consistent with that seen in previous semaglutide trials, and no new safety signals were observed. The incidence of serious adverse events (SAEs) was lower in participants receiving Rybelsus ® than those receiving placebo, mostly due to the higher rate of cardiovascular events and infections in the placebo group. The most common SAEs were cardiac disorders (17.8% and 19.8%, respectively) and infections/infestations (15.0% and 16.5%, respectively) in the Rybelsus ® and placebo arms 1 . In a key secondary analysis from SOUL published simultaneously, oral semaglutide reduced risk of MACE independently of baseline use of SGLT2i and suggests similar benefits in participants with and without concomitant SGLT2i use during trial 7 . SOUL confirmed the well-established safety and tolerability profile of semaglutide supported by long-term safety data with more than 33 million patient years 8 . Based on data from the SOUL clinical trial, Novo Nordisk submitted a label extension application for Rybelsus ® , which has been accepted for review by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA. A decision is anticipated in 2025. About SOUL SOUL was a multicentre, international, randomised, double-blind, parallel-group, placebo-controlled, phase 3 cardiovascular outcomes trial with 9,650 people enrolled. It was conducted to assess the effect of oral semaglutide vs placebo on cardiovascular outcomes in people with type 2 diabetes and established CVD and/or CKD. The SOUL trial was initiated in 2019. The key objective of SOUL was to demonstrate that oral semaglutide lowers the risk of major adverse cardiovascular events (a composite endpoint consisting of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke) compared to placebo, both added to standard of care in patients with type 2 diabetes and established CVD and/or CKD 9,10 . About Rybelsus ® Rybelsus ® (oral semaglutide) is a GLP-1 receptor agonist indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise 11,12 . Rybelsus ® is administered once daily and is approved for use in three therapeutic dosages: 3 mg, 7 mg and 14 mg 13,14 . Rybelsus ® offers superior blood glucose lowering vs Januvia ® and Jardiance ®13,14 , together with consistent weight reduction 13-15 and reduction in cardiometabolic risk factors 15 . Rybelsus ® is currently commercially marketed in 45 countries. More than 2.1 million people with type 2 diabetes are currently being treated with Rybelsus ® worldwide 16 . About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook , Instagram , X , LinkedIn and YouTube . References 1. McGuire DK, et al. Oral presentation presented at the American College of Cardiology Congress Scientific Session & Expo 2025; 29–31 March 2025. Presentation 104-07. 2. McGuire DK., et al. N Engl J Med. 2025, New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2501006 3. Reiter-Brennan C, et al. Curr Cardiol Rep. 2021;23:22. 4. World Health Organization [online]. Available at: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds ) Last accessed: February 2025. 5. Chakraborty S, et al. Clin Med Insights Endocrinol Diabetes. 2023;16:11795514231220780. 6. Mosenzon O, et al. Cardiovasc Diabetol. 2021;20:154 7. Marx N., et al. Circulation 2025: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.125.074545 8. Novo Nordisk data on file. 9. NCT03914326. Available at: https://clinicaltrials.gov/ct2/show/NCT03914326 Last accessed: February 2025. 10. McGuire DK, et al. Diabetes Obes Metab. 2023;25:1932–1941. 11. Rybelsus ® (semaglutide) US PI. 2024 [online]. Available at: https://www.novo-pi.com/rybelsus.pdf Last accessed: March 2025. 12. Rybelsus ® (semaglutide) SmPC. 2025 [online]. Available at: https://www.ema.europa.eu/en/documents/product-information/rybelsus-epar-product-information_en.pdf Last accessed: March 2025. 13. Rodbard HW, et al. Diabetes Care . 2019;42:2272–2281. 14. Rosenstock J, et al. JAMA. 2019;321:1466–1480. 15. Husain M, et al. N Engl J Med. 2019;381:841–851. 16. Novo Nordisk Data on File. IQVIA Ozempic and Rybelsus patient numbers March 2025. SOURCE: Novo Nordisk

Clinical ResultPhase 3Drug ApprovalAHA

29 Mar 2025

·www.novonordisk.com

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide) significantly reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD) 1 . These new data from the phase 3b trial were featured during a late-breaking clinical trial session at the American College of Cardiology's (ACC) Annual Scientific Session and Expo in Chicago, US and simultaneously published today in New England Journal of Medicine 2 . The SOUL trial achieved its primary endpoint, demonstrating a 14% reduction in risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes and CVD and/or CKD when treated with Rybelsus ® compared to placebo. Each component of MACE, being CV death, nonfatal myocardial infarction and nonfatal stroke, contributed to the risk reduction 1 . “Heart attacks and strokes are the leading causes of disability and death for people with type 2 diabetes, and there is a need for new, patient-centric treatments to help manage this risk,” said Darren McGuire, MD, Distinguished Chair in Cardiovascular Science and Teaching Professor of Medicine at UT Southwestern, US, and SOUL steering committee co-chair. “The SOUL trial in adults with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) and/or CKD demonstrated significant reductions in the risk of major cardiovascular events including heart attack, stroke and CV death in those treated with oral semaglutide vs placebo. The proven cardiovascular benefit reflects a profound clinical impact for our patients who now have an oral option to improve health outcomes.” Cardiometabolic diseases span a wide range of conditions, including cardiovascular and peripheral artery disease, type 2 diabetes and chronic kidney disease 3 . When combined, these conditions represent the leading cause of death globally 4 . Having type 2 diabetes directly increases the risk of developing interconnected cardiometabolic diseases, while also contributing to the progression of other cardiovascular risk factors 5 . Nearly one in three adults with type 2 diabetes have CVD 6 . “Novo Nordisk continues to evolve its focus beyond diabetes and obesity towards a broader spectrum of metabolic and cardiovascular health,” said Martin Holst Lange, executive vice president for Development at Novo Nordisk. “These data, alongside our other data being presented at ACC, reinforce the comprehensive set of health benefits of semaglutide, making it a strong option for healthcare professionals addressing the spectrum of metabolic and cardiovascular health – and our continued leadership in the space.” The overall safety profile of oral semaglutide in SOUL was consistent with that seen in previous semaglutide trials, and no new safety signals were observed. The incidence of serious adverse events (SAEs) was lower in participants receiving Rybelsus ® than those receiving placebo, mostly due to the higher rate of cardiovascular events and infections in the placebo group. The most common SAEs were cardiac disorders (17.8% and 19.8%, respectively) and infections/infestations (15.0% and 16.5%, respectively) in the Rybelsus ® and placebo arms 1 . In a key secondary analysis from SOUL published simultaneously, oral semaglutide reduced risk of MACE independently of baseline use of SGLT2i and suggests similar benefits in participants with and without concomitant SGLT2i use during trial 7 . SOUL confirmed the well-established safety and tolerability profile of semaglutide supported by long-term safety data with more than 33 million patient years 8 . Based on data from the SOUL clinical trial, Novo Nordisk submitted a label extension application for Rybelsus ® , which has been accepted for review by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA. A decision is anticipated in 2025. About SOUL SOUL was a multicentre, international, randomised, double-blind, parallel-group, placebo-controlled, phase 3 cardiovascular outcomes trial with 9,650 people enrolled. It was conducted to assess the effect of oral semaglutide vs placebo on cardiovascular outcomes in people with type 2 diabetes and established CVD and/or CKD. The SOUL trial was initiated in 2019. The key objective of SOUL was to demonstrate that oral semaglutide lowers the risk of major adverse cardiovascular events (a composite endpoint consisting of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke) compared to placebo, both added to standard of care in patients with type 2 diabetes and established CVD and/or CKD 9 ,10 . About Rybelsus ® Rybelsus ® (oral semaglutide) is a GLP-1 receptor agonist indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise 11,12 . Rybelsus ® is administered once daily and is approved for use in three therapeutic dosages: 3 mg, 7 mg and 14 mg 13,14 . Rybelsus ® offers superior blood glucose lowering vs Januvia ® and Jardiance ® 13,14 , together with consistent weight reduction 13-15 and reduction in cardiometabolic risk factors 15 . Rybelsus ® is currently commercially marketed in 45 countries. More than 2.1 million people with type 2 diabetes are currently being treated with Rybelsus ® worldwide 16 . About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information _______________________ References 1. McGuire DK, et al. Oral presentation presented at the American College of Cardiology Congress Scientific Session & Expo 2025; 29–31 March 2025. Presentation 104-07. 2. McGuire DK., et al. N Engl J Med. 2025, New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2501006 3. Reiter-Brennan C, et al. Curr Cardiol Rep. 2021;23:22. 4. World Health Organization [online]. Available at: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds ) Last accessed: February 2025. 5. Chakraborty S, et al. Clin Med Insights Endocrinol Diabetes. 2023;16:11795514231220780. 6. Mosenzon O, et al. Cardiovasc Diabetol. 2021;20:154 7. Marx N., et al. Circulation 2025: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.125.074545 8. Novo Nordisk data on file. 9. NCT03914326. Available at: https://clinicaltrials.gov/ct2/show/NCT03914326 Last accessed: February 2025. 10. McGuire DK, et al. Diabetes Obes Metab. 2023;25:1932–1941. 11. Rybelsus ® (semaglutide) US PI. 2024 [online]. Available at: https://www.novo-pi.com/rybelsus.pdf Last accessed: March 2025. 12. Rybelsus ® (semaglutide) SmPC. 2025 [online]. Available at: https://www.ema.europa.eu/en/documents/product-information/rybelsus-epar-product-information_en.pdf Last accessed: March 2025. 13. Rodbard HW, et al. Diabetes Care . 2019;42:2272–2281. 14. Rosenstock J, et al. JAMA. 2019;321:1466–1480. 15. Husain M, et al. N Engl J Med. 2019;381:841–851. 16. Novo Nordisk Data on File. IQVIA Ozempic and Rybelsus patient numbers March 2025.

Clinical ResultPhase 3Drug Approval

26 Feb 2025

·www.drugs.com

Nonarteritic Anterior Ischemic Optic Neuropathy Increased With Semaglutide

WEDNESDAY, Feb. 26, 2025 -- For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION), according to a study published online Feb. 20 in JAMA Ophthalmology . Cindy X. Cai, M.D., from the Johns Hopkins School of Medicine in Baltimore, and colleagues conducted a retrospective study across 14 databases to examine the potential association between semaglutide and NAION. Adults with T2D taking semaglutide, other glucagon-like peptide 1 receptor agonists (GLP-1 RAs; dulaglutide and exenatide), or non-GLP-1 RA medications (empagliflozin, sitagliptin, and glipizide) from Dec. 1, 2017, to Dec. 31, 2023, were included. Of 37.1 million individuals with T2D, there were 810,390 new semaglutide users. The researchers found that among semaglutide users, the incidence rate of NAION was 14.5 per 100,000 person-years. Using the sensitive NAION definition, the hazard ratio for NAION among new users of semaglutide was not different compared with that of the non-GLP-1 RA medications empagliflozin, sitagliptin, and glipizide. Using the specific definition, the risk was higher for semaglutide users compared with patients taking empagliflozin (hazard ratio, 2.27). The risk for NAION was increased in a self-controlled case series analysis of semaglutide exposure (meta-analysis incidence rate ratio, 1.32). "In the absence of a known mechanism for this association, we urge clinicians to weigh the concern for an increased risk of a rare but potentially blinding eye condition with the many therapeutic benefits of semaglutide," the authors write. Several authors disclosed ties to industry. Abstract/Full Text Editorial (subscription or payment may be required) Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

100 Deals associated with Sitagliptin Phosphate

External Link

KEGG	Wiki	ATC	Drug Bank
D06645	Sitagliptin Phosphate	A10BH01	DB01261

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	United States	Merck Sharp & Dohme Corp.	16 Oct 2006

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Inflammation	Phase 3	Canada	Merck Sharp & Dohme Corp.	01 Aug 2015
Diabetes Mellitus	Phase 3	United States	Takeda Pharmaceutical Co., Ltd.	01 Apr 2012
Diabetes Mellitus	Phase 3	Australia	Takeda Pharmaceutical Co., Ltd.	01 Apr 2012
Diabetes Mellitus	Phase 3	Bulgaria	Takeda Pharmaceutical Co., Ltd.	01 Apr 2012
Diabetes Mellitus	Phase 3	Croatia	Takeda Pharmaceutical Co., Ltd.	01 Apr 2012
Diabetes Mellitus	Phase 3	Czechia	Takeda Pharmaceutical Co., Ltd.	01 Apr 2012
Diabetes Mellitus	Phase 3	Hungary	Takeda Pharmaceutical Co., Ltd.	01 Apr 2012
Diabetes Mellitus	Phase 3	Italy	Takeda Pharmaceutical Co., Ltd.	01 Apr 2012
Diabetes Mellitus	Phase 3	Malaysia	Takeda Pharmaceutical Co., Ltd.	01 Apr 2012
Diabetes Mellitus	Phase 3	Slovakia	Takeda Pharmaceutical Co., Ltd.	01 Apr 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00659711 (1928, CTgov)	Not Applicable	Type 2 diabetes mellitus in obese	22	Januvia (Sitagliptin) 100 mg (Januvia 100mg)	dygnucdbre(mxpiolqwil) = lrsirzuszn tdpdumjddx (okqbgkguol, 10) View more	-	21 Jul 2022
				Placebo (Placebo)	dygnucdbre(mxpiolqwil) = jtunkyhimw tdpdumjddx (okqbgkguol, 8) View more
NCT01879228 (CTgov)	Not Applicable	Cystic Fibrosis \| Exocrine Pancreatic Insufficiency	26	Sitagliptin (Sitagliptin)	rtmlybekmc(swtljlehfh) = hmjgpyrerh unhhlvfpkc (mfmaukebvq, vjcevuntqq - lajpszycej) View more	-	09 Feb 2022
				Placebo (Placebo)	rtmlybekmc(swtljlehfh) = mzebhbnkmo unhhlvfpkc (mfmaukebvq, fuhrykzglz - tqvftfnbzx) View more
NCT01928199 (CTgov)	Phase 4	Diabetes Mellitus	61	Sitagliptin (Sitagliptin)	xvnlrmmber(pbgauydavl) = euntbhkcjn piphpngrue (bnblvbdtbr, 62.44) View more	-	29 Jun 2021
				Placebo (Placebo)	xvnlrmmber(pbgauydavl) = cnyxqltxvw piphpngrue (bnblvbdtbr, 72.03) View more
NCT02917031 (MEASURE-HF, CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Heart Failure	348	Placebo to match sitagliptin+Saxagliptin (Saxagliptin)	dmleyfcgwg(fxdzzyeaez) = debbigiegk stdxrjfkdp (xkhslrpfgz, 15.3412) View more	-	18 Jun 2021
				Placebo to match saxagliptin (Placebo)	dmleyfcgwg(fxdzzyeaez) = lvikbpoeyv stdxrjfkdp (xkhslrpfgz, 18.1178) View more
ADA2021	Not Applicable	-	20	Sitagliptin 100 mg/d	ukvcfnsgaj(aptcjfzukt) = bogxqcrtxc qstkbrognb (icedeujidg ) View more	-	01 Jun 2021
				Placebo	ukvcfnsgaj(aptcjfzukt) = adohdfwtcc qstkbrognb (icedeujidg ) View more
NCT02683187 (CTgov)	Phase 1	-	40	Active Comparator: Sitagliptin (Sitagliptin)	xxhzbyxogv(aydyyhokpr) = wdubqxsgly vhxcjvgbff (notaivdggd, ojrwmxftgd - ounsnalpyb) View more	-	03 May 2021
				Placebo Comparator - No Sitagliptin (Non-Sitagliptin)	xxhzbyxogv(aydyyhokpr) = ryvdpmnumo vhxcjvgbff (notaivdggd, jvjzydqufr - pbxdipqxzt) View more
NCT00795275 (1651, CTgov)	Not Applicable	Obesity	26	Sitagliptin Phosphate (Impaired Fasting Glucose)	rmynfxybtj(gdzbvsavfj) = hdedqcatbh nxpmgngghq (ztjqfjriiu, 15) View more	-	05 Apr 2021
				Sitagliptin Phosphate (Normal Glucose Tolerance)	rmynfxybtj(gdzbvsavfj) = kaynsqxtjp nxpmgngghq (ztjqfjriiu, 6) View more
NCT03359590 (CTgov)	Phase 2	Hypoglycemia \| Diabetes Mellitus, Type 2	20	Sitagliptin 100 mg (Sitagliptin Arm)	oucoekzcfr(ouotcntzyd) = gggojukzux iyiemjujqk (otkdnlyqwf, 4.137) View more	-	21 Feb 2021
				Placebo (Placebo Arm)	oucoekzcfr(ouotcntzyd) = dsttqlxjqw iyiemjujqk (otkdnlyqwf, 3.045) View more
NCT02683525 (Prospective Phase II Clinical Trial of CD26/Dipeptidyl Peptidase (DPP)-IV Inhibition for Prevention of Acute Graft Versus Host Disease (aGVHD) Following Myeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation, CTgov)	Phase 2	Acute Graft Versus Host Disease \| Hematopoietic stem cell transplantation	37	sitagliptin	qkmjzlymdd = oknukxbqnp ztzniuvjox (oeadwtzhdm, ndjnuxwfez - oaqulcivgy) View more	-	29 Dec 2020
NCT01485614 (0431-083 \| MK-0431-083, CTgov)	Phase 3	Diabetes Mellitus, Type 2	200	Placebo to metformin+Sitagliptin (Sitagliptin)	wfgbnmmrtw(nqljynekqx) = muvxduapvs qwwulzdgfp (uvbpsajbka, 1.58) View more	-	16 Dec 2020
				Placebo to metformin+Metformin (Placebo/Metformin)	wfgbnmmrtw(nqljynekqx) = zlnyeiigse qwwulzdgfp (uvbpsajbka, 1.45) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Sitagliptin Phosphate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation